Oncology · Androgen Receptor InhibitorRegulatory Approvalregulatorymid-term

FDA Accepts Supplement Application for ERLEADA (Apalutamide)

Importance7/ 10

ActionMonitor

View Company Intelligence

Explore aggregated signals, assets, and competitive context for organizations linked to this signal.

Janssen35 signalsView page

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/8/2026, 6:31:10 PM

Assessment confidence: 51% · The main uncertainty is limited high-relevance corpus coverage for this sub-indication.

Executive Thesis

The FDA's acceptance of the supplemental application for ERLEADA is significant as it may lead to label expansions that enhance the drug's market position. This development underscores the importance of proactive portfolio management in response to regulatory changes. Regulatory context from FDA (FDA AP — ERLEADA (SUPPL)) supports the near-term read. Assessment grounded in 25 ranked evidence items (3 high-relevance).

Strategic Assessment

Portfolio teams should prepare for potential label expansions and market strategies based on the outcomes of this supplemental application. The strongest clinical anchor is A Study of Androgen Receptor (AR) Antagonist Apalutamide in Chinese Participants With Metastatic Castration-Resistant Prostate Cancer (ClinicalTrials.gov), entity match (janssen). In Oncology · Androgen Receptor Inhibitor, 6 regulatory and 4 competitive items passed relevance filtering for Janssen.

Competitive Pressure

The most relevant competitive pressure comes from FDA Accepts NDA for Roche's Giredestrant in Early-Stage ER-Positive Breast Cancer (Humanexa Signals) — sponsor/company relevance (roche). Secondary pressure from FDA Accepts NDA for Roche's Giredestrant in Early-Stage ER-Positive Breast Cancer. This acceptance indicates ongoing support for ERLEADA in the oncology market, potentially enhancing its competitive positioning against other androgen receptor inhibitors.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — ERLEADA (SUPPL) (FDA). Entity match (janssen). The acceptance of the supplemental application indicates a positive regulatory trajectory, but the final approval outcome remains to be seen.

Key Risks

Elevated medium regulatory exposure for Janssen could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

Successful label expansions could improve ERLEADA's market share and revenue potential, particularly in a competitive oncology landscape.
Oncology · Breast Cancer · Regulatory Approval · Giredestrant is positioned to potentially become the new standard-of-care in adjuvant treatment for early-stage ER-positive breast cancer, a significant advancement in over 20 years.
Oncology · Breast Cancer · Regulatory Approval · Giredestrant is positioned to potentially become the new standard-of-care in early-stage ER-positive breast cancer, impacting existing therapies.
CDK4/6 inhibitors (CDK4/6i) represent the standard treatment for HR+/HER2- ABC. The study assessed the efficacy and safety profiles of CDK4/6i from first-line (1 L) to third-line (3 L) in patients with HR+/HER2- ABC from high-altitude versus low-altitude regions.
Upside for Janssen may improve if A Study to Learn How Men With Advanced Prostate Cancer Respond to Treatment With Darolutamide and Hormone Therapy, With or Without Chemotherapy, in Real-world Medical Practice (ClinicalTrials.gov) delivers favorable follow-through.

What Would Change This Assessment

This becomes more urgent if Monitor the FDA's review timeline and any subsequent announcements regarding approval outcomes.
Additional medium- or high-relevance evidence would materially upgrade this assessment.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — ERLEADA (SUPPL)
FDAhigh relevance
Entity match (janssen)
FDA document
View source
IND Application Reporting: IND Safety Reports
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
Investigational New Drug (IND) Application
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
FDA Approves New Treatment That Uses Donor Immune Cells to Prevent Serious Complications in Blood Cancer Patients
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
FDA AP — COPAXONE (SUPPL)
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
FDA AP — COLUMVI (SUPPL)
FDAmedium relevance
Moderate corpus alignment
FDA document
View source

A Study of Androgen Receptor (AR) Antagonist Apalutamide in Chinese Participants With Metastatic Castration-Resistant Prostate Cancer
ClinicalTrials.govhigh relevance
Entity match (janssen)
FDA document
View source
A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy
ClinicalTrials.govhigh relevance
Entity match (janssen)
FDA document
View source
A Study to Learn About Real-world Utilization and Outcomes of Darolutamide and Other Androgen Receptor Pathway Inhibitors (ARPIs) for Newly Diagnosed Metastatic Hormone-sensitive Prostate Cancer (de N
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
The Immune Effects of Fermented Wheat Germ Nutritional Supplementation in Patients With Advanced Solid Tumor Cancers Being Treated With Standard of Care Checkpoint Inhibitors
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
An Observational Study to Learn More About How Medicines That Block Male Hormones Are Used in People With Prostate Cancer in Australia
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
A Study to Learn How Men With Advanced Prostate Cancer Respond to Treatment With Darolutamide and Hormone Therapy, With or Without Chemotherapy, in Real-world Medical Practice
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Effects of Urolithin A Supplementation on Glucose Metabolism in Healthy Adults 55 >= Years Old: A Randomized Triple-Masked Controlled Clinical Trial
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

FDA Accepts NDA for Roche's Giredestrant in Early-Stage ER-Positive Breast Cancer
Humanexa Signalsmedium relevance
Sponsor/company relevance (Roche)
FDA Accepts NDA for Roche's Giredestrant in Early-Stage ER-Positive Breast Cancer
Humanexa Signalsmedium relevance
Sponsor/company relevance (Roche)
Sandoz Receives FDA Approval for Enzalutamide ANDA216068
Humanexa Signalsmedium relevance
Moderate corpus alignment
FDA Approves Supplemental Application for TRUXIMA (Rituximab-ABBS)
Humanexa Signalsmedium relevance
Moderate corpus alignment

Efficacy and safety profiles of CDK4/6 inhibitor in patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer (ABC) from the high
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Targeting lymphotoxin β receptor: from mechanism to precision therapy.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Targeting the PI3K/AKT pathway in prostate cancer: the role of PTEN deficiency and biomarker-guided therapy.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Trial watch: antibody-drug conjugates in cancer therapy.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Selected immunoendocrine and performance adaptations to upper-body plyometric training and β-alanine supplementation in male swimmers.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Intratumoral enrichment and suppressive activity of DP8α regulatory T cells in human colorectal cancer.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Multi-omics analysis of saccharomyces boulardii supplementation reveals coordinated microbiome, metabolic, and immune signaling changes accompanying tumor suppression.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Janssen
ERLEADA
androgen receptor inhibitors

Commercial impact

medium

Successful label expansions could improve ERLEADA's market share and revenue potential, particularly in a competitive oncology landscape.

Regulatory impact

medium

The acceptance of the supplemental application indicates a positive regulatory trajectory, but the final approval outcome remains to be seen.

What to watch

Monitor the FDA's review timeline and any subsequent announcements regarding approval outcomes.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.